December 15, 2025 · Form 4 insider transaction
Matrix Capital Management Company, LP sold 7,500,000 shares of Zentalis Pharmaceuticals, Inc. at $1.33 per share, a transaction worth $9.97M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 0 days after the transaction.
The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.; The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.